Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.
Chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) are among respiratory conditions associated with an increased risk of severe COVID-19 outcomes, a recent study showed. However, the impact of respiratory disease on COVID-19 risk may not be as alarming as initially thought.
Use of omalizumab for treating patients with severe allergic asthma in a real-world setting yields a steroid-sparing effect and helps minimize the occurrence of both clinically significant and severe asthma attacks, as reported in a study.
The specific TSLP* inhibitor tezepelumab significantly reduces exacerbation rates across a broad spectrum of patients with severe, uncontrolled asthma, regardless of the status of key inflammatory biomarkers, according to the NAVIGATOR study presented at ATS 2021.
Interleukin 5 (IL-5) inhibition with mepolizumab appears to improve asthma control, cutting the incidences of exacerbations and hospitalizations, in patients with severe eosinophilic asthma treated in a real-world setting, a study reports.
As few as 2 percent of the general adult population have concomitant asthma, rhinitis, and eczema, according to data from the West Sweden Asthma Study. Furthermore, individuals with the three conditions are most likely to be sensitized to aeroallergens.
Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.
Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.
For mild asthma, as-needed budesonide–formoterol (ICS-LABA*) significantly reduces the short-term risk of severe exacerbations, even with just a single day of increased use, compared with as needed SABA** — and this protective benefit appears as good as that seen with regular use of maintenance ICS, suggests a post hoc analysis of the SYGMA*** 1 study.